Skip to content 
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany. more
| Time Frame | BNTX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -2.03% | 0.28% | -0.82% |
| 1-Month Return | -20.66% | -9.03% | -6.02% |
| 3-Month Return | -8.13% | -6.46% | -6.25% |
| 6-Month Return | -10.85% | 7.24% | -2.8% |
| 1-Year Return | -8.32% | 0.53% | 13.78% |
| 3-Year Return | -29.24% | 14.02% | 62.85% |
| 5-Year Return | -8.81% | 23.96% | 63.02% |
| 10-Year Return | 514.19% | 116.88% | 218.11% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 18.98B | 17.31B | 3.82B | 2.75B | 2.76B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.22,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true},{"date":"2024-12-31","value":14.5,"profit":true},{"date":"2025-12-31","value":14.53,"profit":true}] |
| Cost of Revenue | 2.91B | 3.00B | 599.80M | 541.30M | 616.47M | [{"date":"2021-12-31","value":97.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.03,"profit":true},{"date":"2024-12-31","value":18.07,"profit":true},{"date":"2025-12-31","value":20.58,"profit":true}] |
| Gross Profit | 16.07B | 14.32B | 3.22B | 2.21B | 2.14B | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.11,"profit":true},{"date":"2023-12-31","value":20.04,"profit":true},{"date":"2024-12-31","value":13.76,"profit":true},{"date":"2025-12-31","value":13.32,"profit":true}] |
| Gross Margin | 84.66% | 82.70% | 84.29% | 80.32% | 77.64% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.69,"profit":true},{"date":"2023-12-31","value":99.57,"profit":true},{"date":"2024-12-31","value":94.88,"profit":true},{"date":"2025-12-31","value":91.71,"profit":true}] |
| Operating Expenses | 781.40M | 1.67B | 2.53B | 3.52B | 2.76B | [{"date":"2021-12-31","value":22.17,"profit":true},{"date":"2022-12-31","value":47.47,"profit":true},{"date":"2023-12-31","value":71.76,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":78.43,"profit":true}] |
| Operating Income | 15.28B | 12.64B | 690.40M | (1.31B) | (623.87M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.72,"profit":true},{"date":"2023-12-31","value":4.52,"profit":true},{"date":"2024-12-31","value":-8.6,"profit":false},{"date":"2025-12-31","value":-4.08,"profit":false}] |
| Total Non-Operating Income/Expense | (263.20M) | 622.80M | 845.40M | 1.06B | (396.56M) | [{"date":"2021-12-31","value":-24.79,"profit":false},{"date":"2022-12-31","value":58.67,"profit":true},{"date":"2023-12-31","value":79.63,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-37.36,"profit":false}] |
| Pre-Tax Income | 15.05B | 12.95B | 1.19B | (677.70M) | (1.01B) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.09,"profit":true},{"date":"2023-12-31","value":7.88,"profit":true},{"date":"2024-12-31","value":-4.5,"profit":false},{"date":"2025-12-31","value":-6.71,"profit":false}] |
| Income Taxes | 4.75B | 3.52B | 255.80M | (12.40M) | 81.93M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.04,"profit":true},{"date":"2023-12-31","value":5.38,"profit":true},{"date":"2024-12-31","value":-0.26,"profit":false},{"date":"2025-12-31","value":1.72,"profit":true}] |
| Income After Taxes | 10.29B | 9.43B | 930.30M | (665.30M) | (1.09B) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true},{"date":"2024-12-31","value":-6.46,"profit":false},{"date":"2025-12-31","value":-10.6,"profit":false}] |
| Income From Continuous Operations | 10.29B | 9.43B | 930.30M | (665.30M) | (1.14B) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true},{"date":"2024-12-31","value":-6.46,"profit":false},{"date":"2025-12-31","value":-11.04,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 10.29B | 9.43B | 930.30M | (665.30M) | (1.09B) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true},{"date":"2024-12-31","value":-6.46,"profit":false},{"date":"2025-12-31","value":-10.6,"profit":false}] |
| EPS (Diluted) | 39.69 | 36.93 | 3.83 | (2.81) | (3.87) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":9.65,"profit":true},{"date":"2024-12-31","value":-7.08,"profit":false},{"date":"2025-12-31","value":-9.75,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| BNTX | |
|---|---|
| Cash Ratio | 6.93 |
| Current Ratio | 7.54 |
| Quick Ratio | 7.49 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BNTX | |
|---|---|
| ROA (LTM) | -3.56% |
| ROE (LTM) | -5.88% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| BNTX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.13 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.87 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BNTX | |
|---|---|
| Trailing PE | NM |
| Forward PE | 7.04 |
| P/S (TTM) | 7.66 |
| P/B | 1.02 |
| Price/FCF | 92 |
| EV/R | 1.66 |
| EV/Ebitda | 32.70 |
| PEG | 0.04 |
BioNTech SE (BNTX) share price today is $85.68
Yes, Indians can buy shares of BioNTech SE (BNTX) on Vested. To buy
Yes, you can purchase fractional shares of BioNTech SE (BNTX) via the Vested app. You can start investing in BioNTech SE (BNTX) with a minimum investment of $1.
You can invest in shares of BioNTech SE (BNTX) via Vested in three simple steps:
The 52-week high price of BioNTech SE (BNTX) is $124. The 52-week low price of BioNTech SE (BNTX) is $79.52.
The price-to-earnings (P/E) ratio of BioNTech SE (BNTX) is
The price-to-book (P/B) ratio of BioNTech SE (BNTX) is 1.02
The dividend yield of BioNTech SE (BNTX) is 0.00%
The market capitalization of BioNTech SE (BNTX) is $21.98B
The stock symbol (or ticker) of BioNTech SE is BNTX
Consider the share price of BioNTech SE as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether BioNTech SE has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in BioNTech SE shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the BioNTech SE stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of BioNTech SE and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that BioNTech SE stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
